quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

Crypto News Today: Pepeto Project News While Bull Run Signals Align and Dogecoin SEC Commodity Ruling Opens the Door for What Comes Next

View original at globenewswire.com
Crypto News Today: Pepeto Project News While Bull Run Signals Align and Dogecoin SEC Commodity Ruling Opens the Door for What Comes Next Dubai, UAE, March 28, 2026 (GLOBE NEWSWIRE) -- Pepeto pushed past $8.47 million after its latest round closed ahead of schedule while the crypto news today delivered the catalysts thi…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Analyst targets for Dogecoin in this bull run sit between $0.20 and $0.47, a respectable 2x to 5x for holders

    60% confidence
  • Pepeto organic growth is already outpacing what the team expected

    60% confidence
  • Dogecoin reached $85 billion market cap on community alone and then lost 93% because there was nothing generating demand once the attention moved on

    60% confidence
  • Active wallet addresses jumped 176% in one week

    60% confidence
  • Pepeto presale rounds close faster every week

    60% confidence
  • Binance listing is happening in the few days comings

    60% confidence
  • Binance long ratio on Dogecoin flipped bullish for the first time in months

    60% confidence

Data points we hold from this source

Pepeto · funds raised8.47 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com